Elevated levels of JMJD6 in tumors are linked to unfavorable outcomes and accelerated disease progression across various cancer types, including melanoma,17 prostate10 and breast cancer.19 Through the analysis of a matched human NSCLC tissue array, we observed upregulation of JMJD6 in radioresistant NSCLC cells and patient tumors, which is indicative of a worse prognosis and an elevated risk of metastasis. Here, JMJD6 is linked to melanoma.